Pink Sheet is part of the Informa Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


FDA’s Opioid Guidance: Industry Celebrates Multi-Tiered Labeling Cake

Executive Summary

Endo says label differentiation in the guidance is a positive step; Commissioner Hamburg tells Congress that if new opioid formulations “significantly” deter abuse, generic versions will have to as well.


Related Content

Keeping Track: Opdivo Dosing Simplified; Yosprala, Cuvitru Approved; Telotristat Review Lengthened
Pfizer’s Embeda Joins Abuse-Deterrent Club, But FDA Wants Assurances
Can FDA Finally Put Its Zohydro Problem Behind It?
Abuse-Deterrent Opioid Claims Need Studies, Studies And More Studies
Mixed Messaging: Tier 2 Abuse-Deterrent Opioid Claim Illusive
Purdue’s Abuse-Deterrent Targiniq Is Different – Not Stronger – Than OxyContin
Abuse Reduction Claim In Opioid Label Will Be Difficult To Attain
Opioid Abuse-Deterrent Formulations Could Become Prerequisite To Approval
OxyContin Abuse-Deterrent Formulation Has Addicts Switching To Heroin
Opioid REMS Requires Sponsors To Launch Prescriber Training CME Within 9 Months


Related Companies




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts